Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Zhi tablets in nonalcoholic simple fatty liver disease
CTR20131199Phase 2Suspended
- Sponsor
- Shanghai Fangxin Pharmaceutical Technology
- Start
- Apr 2014
- Countries
- 1
01
Overview
A Phase 2 trial of Shugan Zhi Tablet in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Shanghai Fangxin Pharmaceutical Technology. Started Apr 2014; status: suspended.
02
Drugs
Shugan Zhi Tablet
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20131199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131199.